Abstract
The frequency of vertebral and hip fractures is higher in dialysis patients than in the general population. Decrease of bone mineral density is a risk factor for bone fractures. We selected osteoporotic patients with <70% YAM of lumbar and femoral neck bone mineral density (BMD), to examine the effects of the bisphosphonate ibandronate on bone metabolic markers and BMD. The selected 7 patients were prescribed intravenous ibandronate at a dose of 1mg/month for one year. Serum calcium, phosphate, intact PTH alkaline phosphatase (AlP), tartrate resistant acid phosphatase-5b (TRACP-5b) and lumbar and femoral neck BMD were determined at baseline, and at 6 and 12 months after they were started on ibandronate. Femoral neck BMD had not increased at 6 and 12 months. At 12 months, ALP and TRACP-5b had decreased from 231±45.7 (U/L) and 623±308 (mU/dL) to 166±67.9 (U/L) and 345±199 (mU/dL), respectively.; besides, .lumbar T score had increased from -2.41±0.89 at baseline to -2.00±1.08. None of patients suffered a vertebral or femoral neck fracture during the study period. Ibandronate may improve bone metabolism and lumbar BMD in hemodialysis patients.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call